id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-353528-8a3f5hxu	Levy, Oren	Shattering barriers toward clinically meaningful MSC therapies	2020-07-22		.txt	text/plain	13100	546	34	Although the mechanism of action in human patients is not well elucidated, results from pre-clinical studies of Alofisel indicate that induction of indoleamine 2,3-dioxygenase (IDO) in the presence of inflammatory factors such as interferon- (IFN-) is critical for the therapeutic effect of MSCs. This is because the enzymatic activity of IDO can inhibit T cell function and proliferation and increase the number of regulatory T cells, leading to an increase in anti-inflammatory cytokines [e.g., interleukin-10 (IL-10)] and decrease in pro-inflammatory cytokines [e.g., IFN- and tumor necrosis factor- (TNF-)] (14) . (64) reported that MSCs genetically engineered to express thioredoxin-1 (Trx1)-a powerful antioxidant, transcription factor, and growth factor regulator-improved cardiac function following MI in a rat model compared to unmodified MSCs. Although preclinical Priming MSCs with small molecules is a simple and promising approach to induce the secretion of immunomodulatory and regenerative molecules, but the effect of small molecules only lasts a few hours to a few days.	./cache/cord-353528-8a3f5hxu.txt	./txt/cord-353528-8a3f5hxu.txt